维生素C对危重患者预后的影响:一项Meta分析
该Meta分析检索建库至2019年5月的28项RCT,共纳入4420例危重患者(干预组2207例,对照组2213例),评估抗坏血酸对预后的影响。结果显示干预组与对照组总体死亡率无显著差异(OR=0.90,95%CI 0.75~1.08,P=0.27);结论认为维生素C不降低危重患者总体死亡率,但可缩短ICU和总住院时间,并可降低脓毒症及脓毒性休克患者死亡率和心脏手术术后房颤发生率。
要点
- 总体危重患者:维生素C不降低死亡率(OR=0.90,95%CI 0.75~1.08,P=0.27)。
- 脓毒症和脓毒性休克亚组:维生素C组死亡率低于对照组(OR=0.65,95%CI 0.43~0.99,P=0.04)。
适用人群与场景
- 危重患者,纳入28项RCT共4420例(干预组2207例,对照组2213例)。
- 亚组人群包括脓毒症和脓毒性休克患者、心脏手术患者。
处置流程与药物剂量
- 治疗组接受抗坏血酸,对照组接受安慰剂或其他治疗;原文未报告具体剂量、给药途径、频次或疗程。
研究设计与关键结果
- 研究类型:Meta分析,纳入28项RCT,共4420例危重患者(干预组2207例,对照组2213例)。
- 总体死亡率:干预组与对照组无显著差异(OR=0.90,95%CI 0.75~1.08,P=0.27)。
- 亚组分析:脓毒症和脓毒性休克患者干预组死亡率低于对照组(OR=0.65,95%CI 0.43~0.99,P=0.04)。
- 漏斗图分析显示研究间发表偏倚较小。
证据类型、等级与局限
- 证据类型:Meta分析(纳入28项RCT)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为维生素C不降低危重患者总体死亡率,但可缩短ICU住院时间和总住院时间。
- 作者认为维生素C可降低脓毒症和脓毒性休克患者死亡率,并可降低心脏手术患者术后房颤发生率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
- 另有 8 条提炼内容因数值无法与原文逐一核对而未列出,请以原文为准。
英文原文(摘要)· 点击展开
OBJECTIVE: To systematically evaluate the effect of vitamin C on prognosis of critically ill patients.
METHODS: Randomized controlled trials (RCT) about vitamin C treatment for critically ill patients were searched in CNKI, CBM, VIP database, Wanfang database, PubMed, Springer Link, Embase, Web of Science, and Cochrane Library from their inception to May 2019. Patients in the treatment group received ascorbic acid while patients in the control group received placebo or other treatment. Outcome measures included mortality, the length of intensive care unit (ICU) stay, the length of hospital stay, and incidence of atrial fibrillation. Two researchers were responsible for literature screening, data extraction and quality evaluation independently. Meta-analysis was performed with RevMan 5.2 software. The publication bias was analyzed by funnel plot.
RESULTS: A total of 28 RCTs were enrolled and 4 420 patients were included (2 207 in intervention group and 2 213 in control group). Meta-analysis showed that there was no significant difference in mortality between intervention group and control group [odds ratio (OR) = 0.90, 95% confidence interval (95%CI) = 0.75 to 1.08, P = 0.27]. The length of ICU stay [mean difference (MD) = -0.23, 95%CI = -0.29 to -0.16, P < 0.000 01] and the length of hospital stay (MD = -0.96, 95%CI = -1.21 to -0.70, P < 0.000 01) in intervention group were less than those in control group. Subgroup analysis showed that mortality of patients with sepsis and septic shock in intervention group was lower than that in control group (OR = 0.65, 95%CI = 0.43 to 0.99, P = 0.04). For patients undergoing cardiac surgery, the incidence of postoperative atrial fibrillation in intervention group was lower than that in control group (OR = 0.43, 95%CI = 0.34 to 0.54, P < 0.000 01). It was shown by funnel plot that there was less publication bias among studies.
CONCLUSIONS: Vitamin C does not reduce mortality in critically ill patients, but it can reduce the length of ICU stay and hospital stay. In addition, vitamin C can reduce mortality of patients with sepsis and septic shock and reduce the incidence of atrial fibrillation post operation in patients undergoing cardiac surgery.
参考来源
- Du X, Yang C, Yu X, et al. [Effect of vitamin C on prognosis of critically ill patients: a Meta-analysis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019. PMID: 31537216. doi:10.3760/cma.j.issn.2095-4352.2019.08.006
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。